Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Frederick Locke joins&nbsp;The Lancet Oncology to&nbsp;discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.

CAR T-cell therapy

The Lancet Oncology is a monthly journal, renowned for the publication of high-quality peer reviewed research, reviews and analysis in cancer from around the world. In the monthly podcasts, editors of the journal discuss highlights of the current issue.

Share CAR T-cell therapy

Sign up to save your podcasts

CAR T-cell therapy

CAR T-cell therapy